MCL Literature Feed

In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.

A deep learning model fusing PET/CT and EHR data creates a new signature that better predicts survival in frontline MCL, potentially improving risk-adapted therapy selection.

A real-world, retrospective study demonstrates that clinical next-generation sequencing panels provide significant prognostic and predictive data in mantle cell lymphoma, aiding in the optimization of patient management.

Genomic analysis reveals MCL relapse is driven by the expansion of pre-existing resistant subclones, not new mutations, highlighting the need for deep sequencing at diagnosis to prevent recurrence.

CT-guided anterior approach biopsy is a safe and effective minimally invasive technique for diagnosing orbital lymphoma, including mantle cell lymphoma, providing an alternative to more invasive surgical procedures.

This retrospective analysis evaluates transplant outcomes in relapsed/refractory MCL after ibrutinib failure, identifying risk factors to guide patient selection for this intensive consolidation therapy.

This first real-world analysis of ASCT for MCL in Argentina confirms its efficacy but identifies blastoid variant, age ≥55, and high comorbidities as independent predictors of poor survival.

This large, real-world study demonstrates that any disease progression, even occurring more than 6 years after initial therapy, significantly worsens overall survival in mantle cell lymphoma.

In a resource-limited setting, 12% of chemosensitive MCL patients progress by 3 months while awaiting autologous transplant, highlighting the need for prioritization and defining acceptable wait times.

Real-world data from Germany and Switzerland confirms the effectiveness of brexucabtagene-autoleucel in relapsed/refractory MCL, supporting its use in routine clinical practice beyond trial populations.

An AI-based platform provides more objective and reproducible immunohistochemistry quantification than manual interpretation, improving the diagnostic accuracy in differentiating MCL from CLL/SLL.

High serum sTNFR2 at diagnosis is a strong prognostic biomarker for inferior overall survival in MCL, implicating the tumor microenvironment and suggesting a new therapeutic target.

Absence of CD38 expression in conventional nodal MCL strongly correlates with TP53 inactivation and a distinct genetic profile, identifying a high-risk subgroup via routine flow cytometry.

This German real-world study (2015-2020) reveals rising MCL incidence and poor outcomes, highlighting a dismal median OS of 3.0 months after cBTKi discontinuation, underscoring a critical unmet need.

In a real-world R/R MCL cohort, zanubrutinib demonstrated significantly longer overall survival versus ibrutinib and favorable trends versus acalabrutinib, guiding clinical selection of covalent BTKis.

A family history of hematological malignancy is associated with inferior event-free survival in mantle cell lymphoma, suggesting it may be a novel adverse prognostic factor.

Zanubrutinib plus age-adapted bendamustine-rituximab induction followed by zanubrutinib maintenance demonstrates high efficacy (75% 2-year PFS) and deep responses (94% uMRD) in elderly, frontline MCL patients.

This Chinese real-world study characterizes the clinical features and poor prognosis of blastoid/pleomorphic MCL, providing data to help risk-stratify and manage this aggressive subtype.

This first comprehensive proteogenomic analysis of MCL demonstrates that integrating protein data with genomics improves survival prediction and identifies molecular subtypes linked to IGHV/CCND1 mutations, offering new prognostic tools.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

This large epidemiological study identifies mantle cell lymphoma as one of the most frequent and aggressive nodal non-Hodgkin lymphoma subtypes in North Africa, highlighting regional disease patterns.

Bridging radiotherapy before CAR-T effectively controls disease in MCL patients, with most showing rapid tumor reduction and no local progression, supporting its use as a pre-CAR-T strategy.

This real-world study identifies key patient and systemic barriers limiting CAR-T therapy access for relapsed/refractory MCL, highlighting disparities between trial eligibility and clinical practice.

This large real-world study shows second primary malignancies in MCL patients double mortality risk versus non-MCL patients, mandating long-term surveillance for these subsequent cancers.

This longitudinal study reveals MCL acquires new high-risk genetic features after chemoimmunotherapy, explaining relapse and emphasizing the need for genomic profiling to guide subsequent therapies.

This large retrospective study shows rituximab maintenance after first-line bendamustine-rituximab significantly improves both event-free and overall survival, supporting its use as a standard of care.

In a retrospective ZUMA-2 analysis, prior ibrutinib exposure, versus acalabrutinib, improved brexu-cel CAR-T efficacy and PFS by inducing a more favorable cytotoxic T-cell phenotype.

This US real-world study describes treatment patterns and outcomes for covalent BTK inhibitors in relapsed/refractory MCL, providing crucial benchmarks for routine clinical practice outside of trial settings.

High expression of the lncRNA MALAT1 is a novel, independent biomarker for favorable prognosis in MCL, inversely correlating with proliferation signatures and EZH2 activity.

This retrospective study found one case of occult mantle cell lymphoma in 1328 adult tonsillectomies for benign indications, underscoring the value of routine histopathology for unexpected diagnoses.